Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Veterans

Psilocybin for Veterans

9 papers and 7 clinical trials exploring psilocybin as a treatment for veterans.

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationApproximately 1 in 10 veterans are diagnosed with PTSD and around 30% of veterans experience depression.

Veterans

Psychedelic treatments are emerging as promising therapeutic options for veterans dealing with mental health conditions, particularly post-traumatic stress disorder (PTSD) and treatment-resistant depression. Recent clinical trials highlight the efficacy of compounds such as MDMA and psilocybin in alleviating symptoms and improving overall quality of life.

Full Veterans profile

Academic Research

9 papers
Paywallindividual

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression

This secondary analysis of an open-label trial (n=15) examined a single 25 mg dose of psilocybin with psychological support in veterans with treatment-resistant depression, focusing on anxiety, quality of life, functioning, and PTSD symptoms. Improvements were observed across these measures, but most were no longer significant after accounting for concurrent improvements in depression.

Published
June 4, 2026
Journal
Journal of Affective Disorders
Authors
Kelly, C. M., Fradet, M., Bostian, C. M., Donnelly, A., Ellis, S., Ostacher, M., Aaronson, S., Suppes, T.
Paywallindividual

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study

This open-label follow-up study (n=10) of Veterans with severe treatment-resistant depression (TRD) found that a single dose of psilocybin (25mg) significantly reduced depression for up to 12 months, though effects began to wane after 6 months, with 40% maintaining response and 30% maintaining remission at the 12-month follow-up.

Published
November 1, 2025
Journal
Journal of Affective Disorders
Authors
Ellis, S., Bostian, C., Donnelly, A., Feng, W., Eisen, K., Lean, M., Conlan, E., Ostacher, M., Aaronson, S., Suppes, T.
Open Accessindividual

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat

In a preliminary uncontrolled study of 21 veterans with traumatic brain injury, participation in two psilocybin retreat ceremonies was associated with large reductions in PTSD, depression and anxiety symptoms and with EEG changes (reduced frontal/temporal delta–theta power and increased alpha–beta coherence) consistent with improved emotional regulation and neural communication. These findings suggest psilocybin retreats may improve psychological wellbeing and brain connectivity in veterans with TBI and warrant larger, controlled trials.

Published
August 6, 2025
Journal
Frontiers in Psychiatry
Authors
Blest-Hopley, G., Pasculli, G., Ruffell, S. G. D., Tsang, WF., Emmanuel, O., Pate, K. M., Kettner, H., Roseman, L., Erritzoe, D., Carhart-Harris, R. L.
Open Accessindividual

Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings

Veterans attending naturalistic psilocybin or ayahuasca retreats showed significant improvements across eight mental‑health and reintegration measures, with the largest reductions in depression (PHQ‑9, 29.1%) and PTSD (PCL‑5, 26.1%). Psilocybin retreats produced greater gains on most outcomes while ayahuasca yielded slightly larger PTSD improvement; those with worse baseline symptoms benefited most, with some gender-specific differences.

Published
July 7, 2025
Journal
Brain and Behavior
Authors
Calnan, M., Blest-Hopley, G., Busch, C., Adams, M., Ruffell, S. G. D., Piper, T., Roseman, L., Kettner, H., Carhart-Harris, R.
Paywallindividual

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study

This open-label trial (n=15) evaluates the efficacy and safety of psilocybin (25mg) in veterans with severe treatment-resistant depression (TRD). It finds that 60% of participants met response criteria and 53% met remission criteria at 3 weeks post-treatment, with 47% maintaining response and 40% maintaining remission at 12 weeks.

Published
January 1, 2025
Journal
Journal of Affective Disorders
Authors
Ellis, S., Bostian, C., Feng, W., Fischer, E., Schwartz, G., Eisen, K., Lean, M., Conlan, E., Ostacher, M., Aaronson, S., Suppes, T.
Open Accessmeta

Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement

A multidisciplinary group produced a consensus ethics and policy framework for integrating government‑approved psychedelic medicines into clinical care, articulating 20 consensus points across five core ethical domains. The statement assigns responsible actors for implementation and identifies areas for further research and policy deliberation to promote equitable, safe adoption in mainstream medicine.

Published
June 4, 2024
Journal
JAMA Network Open
Authors
McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C. S., Harvey, I., Kious, B., Marks, M., Mithoefer, M. C., Nielson, E. M., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., Yaden, D. B.

Clinical Trials

7 trials
Not yet recruitingPhase III

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

This Phase III, randomised, quadruple‑masked, parallel trial (n=240) will evaluate the efficacy and risks of psilocybin for treatment‑resistant depression in U.S. military veterans with and without concurrent post‑traumatic stress disorder, with the primary outcome being change in the Montgomery‑Åsberg Depression Rating Scale (MADRS) at 2 weeks. This multi‑site study randomises participants to either a psilocybin intervention dose or a psilocybin comparator dose under blinded conditions. Consenting veterans will receive two psilocybin dosing sessions with psychological preparation, administration and integration support from a facilitator; participants are randomised at the first administration to one of the two doses and one month later all participants receive a 25 mg dose at the second session. Outcomes are measured by an independent evaluator masked to treatment at 2 and 4 weeks after each dosing session, with longer‑term follow‑up over 6 months, and both expected and unanticipated adverse events collected. Key eligibility includes English‑speaking U.S. veterans aged 18–75 years with a current major depressive episode (MADRS ≥20) who have not responded to ≥2 adequate antidepressant treatments.

Started
June 1, 2026
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT07226232
WithdrawnPhase II

Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies

This Phase II, non-randomised, open-label, parallel-group trial (n=150) will study response to three neuroplasticity-enhancing interventions in civilian and Veteran adults (aged 18–69) at low, intermediate or high risk for self-harm. The study will evaluate clinical change in suicidal ideation (Scale of Suicidal Ideation from baseline to the post‑treatment visit at Month 6) and aim to characterise neurobiological and blood-based markers associated with risk and treatment response. Participants are allocated to one of three experimental arms: two sessions of fMRI neurofeedback targeting amygdala activity, an accelerated theta burst stimulation programme of 50 sessions delivered to the dorsolateral prefrontal cortex, or psilocybin‑assisted therapy comprising three preparation sessions, two psilocybin administration sessions and two integration sessions. Baseline and post‑treatment assessments include clinical measures, structural and functional MRI and blood sampling for circular RNA (circRNA); an artificial intelligence analytic team will use these multimodal data to develop predictive models of behavioural risk and treatment response.

Started
May 1, 2026
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT07484906
RecruitingPhase I

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) (PAM-VET)

This Phase I, double-blind, active-controlled trial (n=40) will investigate the safety and potential therapeutic effects of co-administered MDMA and psilocybin in military Veterans diagnosed with post-traumatic stress disorder (PTSD).

Started
June 1, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06989957
RecruitingPhase II

State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma (STARLIGHT)

Open-label, single-group Phase II trial (n=15) of psilocybin-assisted therapy in US military veterans with PTSD: two oral psilocybin sessions (15 mg then 25 mg) plus preparatory and integration psychotherapy.

Started
January 30, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06888128
Unknown statusPhase II

Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans

Interventional single-group study (n=8) assessing acceptability, feasibility, safety, and preliminary efficacy of Psilocybin-Assisted Psychotherapy (two 25 mg oral sessions) plus Cognitive Processing Therapy in military veterans with PTSD.

Started
June 1, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05876481
Active not recruitingPhase II

Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

Single-group Phase II study (n=15) testing two doses of oral psilocybin (15 mg then 25 mg, two sessions ~2 weeks apart) with preparatory and integration psychotherapy in US military Veterans with PTSD.

Started
January 1, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05554094

Explore further

Search all Psilocybin papers Search all Veterans trials Full Psilocybin profile Full Veterans profile